Antibiotic Development

 

 

This track covers everything from discovery through to commercialization and payment reform. Learn about the latest innovative pre-clinical, clinical, commercial pathways, and best practices in traditional and nontraditional antibiotic development. Dive into conversations on “pull” incentives with industry leaders, heads of commercial development and policymakers.

 

Antibiotic R&D, Thursday 7 November 2019

Kevin Outterson
08:30

Keynote Address: A vision for a healthy antibiotic R&D ecosystem

Concrete Commercial Initiatives

Jonathan Van-Tam
08:40

Keynote address: UK’s efforts to combat resistance and create a sustainable commercial environment for existing and future antibiotics

09:20

Sponsored keynote address

TITLE SPONSOR SLOT
10:20

SPEED NETWORKING FOLLOWED BY NETWORKING COFFEE BREAK

Early Development

John Prendergast
Antibiotic R&D
11:15

How synthetic antibiotic development can change the antibiotic treatment model

Mark Albrecht
Antibiotic R&D
11:35

How BARDA Incentivizes antibacterial development from early development through marketing approval

Saransh Chaudhary
Antibiotic R&D
11:55

Oral Ceftriaxone - a proof-of-concept for a novel drug delivery platform

Saransh Chaudhary, Chief Executive Officer, Venus Medicine Research Centre
Sheila Connelly
Antibiotic R&D
12:15

How degrading residual antibiotics in the GI tract may prevent the emergence of anti-microbial resistance in the gut microbiome

12:35

Networking Lunch Break

ROUNDTABLES (1-hour roundtable sessions split between 2 rounds of 30min)

Ryan Devies
14:10

Roundtable: Advancing Preclinical – working with regulators through pre-clinical to advance distinct classes of small molecule drugs

Colm Leonard
14:10

Roundtable: Antimicrobial value assessment - a look into the role of HTA in the UK's testing of novel assessment and delinked payment program

Marco Taglietti
14:10

Roundtable: Candida auris - a ticking time bomb: responding to an urgent global public health threat

Kartik Cherabuddi
14:10

Roundtable: Controlling c.dif - determining who to test and how to prevent additional outbreaks in the hospital

Justine Ross
14:10

Roundtable: Customizing Epic – the use of Epic Stewardship Navigator to aid antimicrobial stewardship, pharmacist workflow, and prescribing habits in a tertiary cancer center

Richard Vickers
14:10

Roundtable: Innovation & stewardship

Advancing narrow spectrum, new mechanism antibiotics as precision agents to by-pass resistance and to support antibiotic stewardship. Developing the right antibiotic to treat the right patient and improve clinical outcomes.
Christine Årdal
14:10

Roundtable: Market Access - overcoming access barriers for smaller markets - considerations for countries and developers

Brian Tse
14:10

Roundtable: Non-traditional antibacterials – advancing non-traditional product types from discovery phase to clinical development

Christian Lillis
14:10

Roundtable: Patient Advocacy - what can the growing antibiotic patient advocacy community do to generate public awareness and support for AMR initiativ

Dave Ousterout
14:10

Roundtable: Phage development - Opportunities in development of novel phage therapies

Jay K Varma
14:10

Roundtable: Policy in Africa- advancing advocacy, political commitment, resistance data collection and Africa-wide stewardship guidelines for antimicrobial use in humans

Jane Knisely
14:10

Roundtable: Supporting development

NIH programs filling the gaps in traditional and non-traditionaltherapeutic discovery & development with grants, contracts,in-vitro and in vivo screening and manufacturing capabilities and more.
Amy Kirby
14:10

Roundtable: Water Quality – understanding transmission of waterborne pathogens and how the international community can combat the spread of resistance through integrating advanced lab techniques and t

Amy Kirby, Senior Service Fellow, Microbiologist, Waterborne Disease Prevention Branch DFWED-NCEZID, CDC

Trial Design

Cara Cassino
Antibiotic R&D
15:15

Novel Trial Designs for non-traditional anti-infectives – Lessons learned from the Exebacase superiority design trial

Michael P Bevilacqua
Antibiotic R&D
15:35

Working with regulators to advance non-traditional therapies to prevent and treat life-threatening infections in surgery and trauma

16:35

Networking coffee break

Supported by BD

18:15

Drinks Reception

last published: 31/Jul/19 21:55

Antibiotic R&D, Friday 8 November 2019

Tom Lowery
09:25

Sponsored keynote address will be delivered by T2 Biosystems

10:30

Networking coffee break

Commercial & Partnerships

Jenny Hellman
Antibiotic R&D
11:15

Pilot reimbursement models to ensure access of new antibiotics in Sweden - Collaboration between industry and government agencies to ensure a model that works for all stakeholders

Monika Schneider
Antibiotic R&D
11:35

Short and long-term payment strategies for a sustainable market – impact of NTAP modifications, DRG carve-out, and potential subscription models

12:35

Networking Lunch Break

13:40

Networking Lunch Break Resumes

ROUNDTABLES (1-hour roundtable sessions split between 2 rounds of 30min)

Minh-Hong Nguyen
14:10

Developing diagnostics – novel approaches to development

Minh-Hong Nguyen, Director, Transplant Infectious Diseases, Director, Antimicrobial Management Program, University of Pittsburgh
Eugean Jiwanmall
14:10

Roundtable: Evaluating Diagnostics – Criteria for potential coverage and related decisions - paths for generating, formalizing, & analysing evidence to build & reach consensus

Thomas Heymann
14:10

Roundtable: AMR and Sepsis - we are all in this together

Jeanette Mucha
14:10

Roundtable: CARB-X Accelerator – Company perspective on CARB-X Accelerator - What worked and what can be improved?

Abigail Colson
14:10

Roundtable: Health Technology Assessment – when it comes to AMR, will HTA be part of the solution or part of the problem?

Lee Jones
14:10

Roundtable: Infection intervention - Using the microbiome to make antibiotics effective again

Angella Browne
14:10

Roundtable: Infection prevention – next wave of infection prevention of multidrug resistant infections through screening, protocol and more

Clifford Mcdonald
14:10

Roundtable: Microbiome & CDC – Discussing a vision for precision public health novel approaches to treating infection prevention through the microbiome

Mary Millard
14:10

Roundtable: Patient practitioner education – how hospitals can and should educate patients on infection risks and easy to implement prevention practices

Eili Klein
14:10

Roundtable: Surveillance

Examining novel metrics for measurement, societal and socioeconomic factors effecting resistance, and how resistance surveillance tools can help educate policymakers on AMR.
Nick Van Hise
14:10

Roundtable: The fecal microbiome - new approaches to the treatment of C. difficile infection

Wes Kim
14:10

SPARK Platform: Pew Charitable Trusts’ Collaborative Discovery Tool for Gram-Negative Antibiotics

Business Models & Partnership

Antibiotic R&D
15:15

SILVER SPONSOR SESSION

If you are interested in sponsoring this session in the Antibiotic R&D Track, contact André Singer now at+1 646 619 1797 or andre.singer@terrapinn.com.
Zak Zimmerman
Antibiotic R&D
15:35

Innovative business partnerships to build a portfolio of novel antibiotics

Terry Roemer
Antibiotic R&D
15:55

Rationale for in-licensing early stage antibacterial assets

last published: 31/Jul/19 21:55

 

 


GET INVOLVED AT

WORLD ANTI-MICROBIAL RESISTANCE CONGRESS

 

To Sponsor Or Exhibit

 


André Singer
andre.singer@terrapinn.com
+1 646.619.1797

 

 

Press & Media Partnerships

 


Shannon McGorry
shannon.mcgorry@terrapinn.com
+1 646.619.1840

 

 

To Speak

 


Claire Murphy
claire.murphy@terrapinn.com
+1 646.619.1784

 

Sign Up for Event Updates